Acorda Therapeutics (ACOR)

Acorda Therapeutics (ACOR) Stock Price & Analysis


ACOR Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.26 - $1.72
Previous Close$0.58
Average Volume (3M)215.98K
Market Cap
Enterprise Value$149.30M
Total Cash (Recent Filing)$37.54M
Total Debt (Recent Filing)$172.92M
Price to Earnings (P/E)-0.1
May 04, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.76
Shares Outstanding24,337,696
10 Day Avg. Volume97,442
30 Day Avg. Volume215,978
Standard Deviation0.41
Financial Highlights & Ratios
Price to Book (P/B)-0.06
Price to Sales (P/S)0.12
Price to Cash Flow (P/CF)7.40
P/FCF Ratio-0.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.26
Enterprise Value/Gross Profit1.69
Enterprise Value/Ebitda5.38
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Acorda Therapeutics’s price range in the past 12 months?
Acorda Therapeutics lowest stock price was $0.26 and its highest was $1.72 in the past 12 months.
    What is Acorda Therapeutics’s market cap?
    Currently, no data Available
    When is Acorda Therapeutics’s upcoming earnings report date?
    Acorda Therapeutics’s upcoming earnings report date is May 04, 2023 which is in 36 days.
      How were Acorda Therapeutics’s earnings last quarter?
      Acorda Therapeutics released its earnings results on Mar 09, 2023. The company reported $0.438 earnings per share for the quarter, beating the consensus estimate of N/A by $0.438.
        Is Acorda Therapeutics overvalued?
        According to Wall Street analysts Acorda Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Acorda Therapeutics pay dividends?
          Acorda Therapeutics does not currently pay dividends.
          What is Acorda Therapeutics’s EPS estimate?
          Acorda Therapeutics’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Acorda Therapeutics have?
          Acorda Therapeutics has 24,337,696 shares outstanding.
            What happened to Acorda Therapeutics’s price movement after its last earnings report?
            Acorda Therapeutics reported an EPS of $0.438 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -19%.
              Which hedge fund is a major shareholder of Acorda Therapeutics?
              Among the largest hedge funds holding Acorda Therapeutics’s share is Canyon Capital Advisors LLC. It holds Acorda Therapeutics’s shares valued at N/A.


                Acorda Therapeutics Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Acorda Therapeutics

                Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.


                Top 5 ETFs holding ACOR

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold ACOR. The ETFs are listed according to market value of ACOR within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Skye Bioscience
                Aptevo Therapeutics
                Corbus Pharmaceuticals

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis